Biogen announced positive results from the Phase 2 part of the AMETHYST Phase 2/3 study (part A) of investigational therapy, ...

Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 study of ...

Cybin Inc (NASDAQ:HELP) is among the best psychedelic stocks to buy in 2026. Toronto, Canada-based Cybin Inc. is also known ...

Data presented by Johnson & Johnson at the 2026 European Lung Cancer ConferencePARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) ...

Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting ...

(NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that its ...

In a phase 2 trial of a novel antihypertensive agent, multiple doses lowered plasma angiotensinogen to a greater extent than a single dose, but did not provide further blood pressure lowering, ...

Kardigan’s tonlamarsen reduced a key biomarker for hypertension in a phase 2 trial, but missed the study’s other goal of significantly reducing blood pressure. The biotech evaluated monthly 90 mg ...

A first-in-class monoclonal antibody has shown significant reductions in skin disease in patients with cutaneous lupus erythematosus (CLE). Litifilimab met the primary endpoint of reduction of disease ...

The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep ...

We recently compiled a list of the 10 Quality Value Stocks Likely to Make a Comeback According to Analysts. BioMarin ...